Good evening :)
$
₹
Creative Medical Technology Holdings Inc

Creative Medical Technology Holdings Inc

CELZ

NASDAQ
Asset Logo

Creative Medical Technology Holdings Inc

CELZ

NASDAQ
$0.662.46% (+0.01)
$
₹
$0.662.46% (+0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $5.1M the stock is ranked 5954

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.54
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.07
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Price Upside

+2869.56%

Earnings Growth

+54.44%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 2869.56% growth, versus a trailing 3-year CAGR of -46.10%.

2026
Current$0.67Baseline
Analyst Target - 1 year
Target$20+2869.56%

All values in $

202220232024202520262027$5.95$11.30$16.65Target+2869.56%
2026
Current$0.67Baseline
Analyst Target - 1 year
Target$20+2869.56%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.59Baseline
Forecast for Dec 2026
High$-1.18+54.44%
Average$-1.18+54.44%
Low$-1.18+54.44%

All values in $

2021202220232024202520265.02-4.57-3.69-3.71-2.59Low+54.44%Average+54.44%High+54.44%
2025
Current$-2.59Baseline
Forecast for Dec 2026
High$-1.18+54.44%
Average$-1.18+54.44%
Low$-1.18+54.44%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-1.2
0
-1.8
-1.4
-1.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000000000
Net Income-1.04-1.55-1.04-1.85-1.63-1.23-1.23-1.88-1.40-1.51
Net Profit Margin-34718.13%-19471.6%--61802.46%-54603.23%---62922.46%--
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Creative Medical Technology Holdings Inc -0.54-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CELZ with any stock or ETF
Compare CELZ with any stock or ETF
Comparing from
CELZ
ABBV
AMGN
Loading...

Frequently asked questions

  1. Creative Medical Technology Holdings Inc (CELZ) share price today is $0.66 as of November 5, 2026 at 8:25 PM IST. The stock touched a day high of $0.68 and a day low of $0.66.

  2. Creative Medical Technology Holdings Inc stock trades on NASDAQ under the ticker symbol CELZ.

  3. Creative Medical Technology Holdings Inc's market capitalization is $5.11M as of November 5, 2026 at 8:25 PM IST.

  4. Creative Medical Technology Holdings Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Creative Medical Technology Holdings Inc's price-to-book (P/B) ratio is 0.54 as of November 5, 2026.

  6. Yes, You can buy Creative Medical Technology Holdings Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Creative Medical Technology Holdings Inc shares in three steps: 1. Search Creative Medical Technology Holdings Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Creative Medical Technology Holdings Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Creative Medical Technology Holdings Inc (CELZ) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 14.97 shares at the current price of $0.66.

Loading...